Tempest Therapeutics Inc Share Price Today: Live Updates & Key Insights

Tempest Therapeutics Inc share price today is $2.28, up 6.02%. The stock opened at $2.18 against the previous close of $2.16, with an intraday high of $2.3 and low of $2.13.

Tempest Therapeutics Inc Share Price Chart

Tempest Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Tempest Therapeutics Inc Share Price Performance

$2.28 0.0602(6.02%) TPST at 23 Mar 2026 03:33 PM Biotechnology
Lowest Today 2.13
Highest Today 2.3
Today’s Open 2.18
Prev. Close 2.16
52 Week High 12.23
52 Week Low 2.12
Day’s Range: Low 2.13 High 2.3
52-Week Range: Low 2.12 High 12.23
1 day return -
1 Week return +5.02
1 month return -7.25
3 month return -24.83
6 month return -75.68
1 year return +177.47
3 year return +63.12
5 year return -93.18
10 year return -

Tempest Therapeutics Inc Institutional Holdings

Versant Venture Management LLC 2.00

Sabby Management LLC 1.32

Vanguard Group Inc 1.21

Vanguard Total Stock Mkt Idx Inv 0.78

Geode Capital Management, LLC 0.33

BlackRock Inc 0.29

Vanguard Institutional Extnd Mkt Idx Tr 0.26

FMR Inc 0.25

Fidelity Extended Market Index 0.18

DRW Securities, LLC 0.14

Abante Quant Value FI 0.10

Dimensional Fund Advisors, Inc. 0.08

UBS Group AG 0.08

NT Ext Equity Mkt Idx Fd - L 0.08

Fidelity Total Market Index 0.06

Spartan Extended Market Index Pool F 0.04

Northern Trust Extended Eq Market Idx 0.03

Fidelity Series Total Market Index 0.03

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.03

Dimensional US Core Equity 1 ETF 0.03

DFA US Vector Equity Class F 0.03

DFA US Core Equity Class F 0.03

Blackrock Extended Mkt Fund CF 0.02

NT Ext Equity Mkt Idx Fd - NL 0.02

Extended Equity Market Fund K 0.02

Spartan Total Market Index Pool G 0.02

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.02

Vanguard Instl Ttl Stck Mkt Idx Tr 0.02

Morgan Stanley - Brokerage Accounts 0.02

Advisor Group Holdings, Inc. 0.01

Tower Research Capital LLC 0.01

Atlantic Trust Group, LLC 0.01

Extended Equity Market Fund M 0.00

Federation des caisses Desjardins du Quebec 0.00

SBI Securities Co Ltd 0.00

Bank of America Corp 0.00

Parallel Advisors, LLC 0.00

BNP Paribas Arbitrage, SA 0.00

NATIONAL BANK OF CANADA /FI/ 0.00

Wells Fargo & Co 0.00

Tempest Therapeutics Inc Market Status

Strong Buy: 0

Buy: 0

Hold: 2

Sell: 0

Strong Sell: 0

Tempest Therapeutics Inc Fundamentals

Market Cap 30.87 M

PB Ratio 4.6098

PE Ratio 0.0

Enterprise Value 30.68 M

Total Assets 41.49 M

Volume 294115

Tempest Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:null 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-31106000 -31.1M, FY22:-36778000 -36.8M, FY21:-29550000 -29.6M, FY20:-19118000 -19.1M, FY19:-44568000 -44.6M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:486000 0.5M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-66000 -0.1M, Q2/2025:-67000 -0.1M, Q1/2025:-68000 -0.1M, Q3/2024:null 0.0M, Q2/2024:-155000 -0.2M

Quarterly Net worth Q3/2025:-3511000 -3.5M, Q2/2025:-7870000 -7.9M, Q1/2025:-10860000 -10.9M, Q3/2024:-10556000 -10.6M, Q2/2024:-9570000 -9.6M

About Tempest Therapeutics Inc & investment objective

Company Information Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Organisation Biotechnology

Employees 24

Industry Biotechnology

CEO Dr. Matthew Angel Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Tempest Therapeutics Inc FAQs

What is the share price of Tempest Therapeutics Inc today?

The current share price of Tempest Therapeutics Inc is $2.28.

Can I buy Tempest Therapeutics Inc shares in India?

Yes, Indian investors can buy Tempest Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Tempest Therapeutics Inc shares in India?

You can easily invest in Tempest Therapeutics Inc shares from India by:

Can I buy fractional shares of Tempest Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Tempest Therapeutics Inc?

Tempest Therapeutics Inc has a market cap of $30.87 M.

In which sector does Tempest Therapeutics Inc belong?

Tempest Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Tempest Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Tempest Therapeutics Inc?

The PE ratio of Tempest Therapeutics Inc is N/A and the PB ratio is 4.61.